During Thursday’s Current trade, Shares of Sunedison Semiconductor Ltd (NASDAQ:SEMI), gain 0.54% to $17.84.
Sunedison Semiconductor Ltd (SEMI) is presently the world’s leading renewable energy developer. In May last year, the company divested its semiconductor business and got it listed on the Nasdaq Global Select Market. The divestment was prompted by lower-than-predictable demand for its semiconductor wafers and enabled it to focus more on its core solar power business.
Solar project sales have picked up as a result of raised photo voltaic (PV) installations across the U.S., China, Japan, India, Middle East, Africa, Latin America, Australia and Southeast Asia. Therefore, sale of the remaining stake, i.e. 10.6 million shares, in the semiconductor business will raise nearly $193 million which it can invest across various countries.
The rising global demand for cheap and clean energy due to environmental concerns and depleting natural resources is benefiting SunEdison. According to Bloomberg, global solar and wind energy project installations in 2015 are likely to enhance to 52,000 megawatts (MW) and 60,000 MW, respectively. Of this, a noteworthy portion is predictable to be in the emerging countries and SunEdison is well positioned to capitalize on this.
Over the past several months, SunEdison has been aggressively investing across emerging markets, particularly India. In fact, in June, SunEdison declared its intention to expand its Indian base by investing about $15 billion through 2022. The company plans to develop 15 gig watts (GW) solar and wind projects in the country.
It is worth mentioning that in January, the world’s leading renewable energy developer reached a planned alliance with the Indian conglomerate, Adani Enterprises, to expand its base in India. Under the agreement, the companies will invest about $4 billion to develop solar PV projects in Gujarat.
SunEdison Semiconductor Limited develops, manufactures, and sells silicon wafers for the semiconductor industry in the United States and internationally. The company provides polished wafers for various applications, counting memory, analog, radio frequency (RF) devices, digital signal processors, and power devices; EPI wafers that enhance the reliability and decrease the power consumption of semiconductor devices in mobile device and cloud infrastructure applications; and SOI wafers, which enhance switching speeds and the performance of RF devices, such as power amplifiers, switches, and sensors.
Shares of HomeAway, Inc. (NASDAQ:AWAY), declined -0.16% to $31.14, during its current trading session.
via PRWEB - HomeAway, Inc. (AWAY), the world leader in vacation rentals, declares its mobile app will now make it easier for families to find child care and purchase tickets to events and attractions while on vacation, thanks to integrations with Care.com (CRCM), Ticket Evolution and GetYourGuide.
Care.com is the world’s largest online destination for finding and managing family care, with 15.2 million members, spanning 16 countries. The company’s ability to assist HomeAway(R) guests find a babysitter fills a large need — more than 70 percent of people using HomeAway.com travel with their family or a group and the average party has at least one child, according to company data.*
In addition, finding and gaining access to local events and attractions in vacation destinations will be easier thanks to integrations with Ticket Evolution and GetYourGuide.
Ticket Evolution operates one of the world’s largest ticketing exchanges, enabling HomeAway guests to seamlessly find tickets to more than 65,000 events worldwide. Meanwhile, GetYourGuide collects and categorizes all the world’s things to do so travelers research less and do more, from skipping attraction lines and guided tours to cooking classes and canal cruises.
HomeAway, Inc., together with its auxiliaries, operates an online vacation rental property marketplace that enables property owners and managers to market properties for rental to vacation travelers. The company’s portfolio comprises vacation rental Websites, such as HomeAway.com, VRBO.com, and VacationRentals.com in the United States; HomeAway.co.uk and OwnersDirect.co.uk in the United Kingdom; HomeAway.de in Germany; Abritel.fr and Homelidays.com in France; HomeAway.es and Toprural.com in Spain; AlugueTemporada.com.br in Brazil; HomeAway.com.au and Stayz.com.au in Australia; and Bookabach.co.nz in New Zealand.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), during its Thursday’s current trading session decreased -1.28% to $11.94.
PharmaEngine, Inc. (TWO) declared that (1) its license partner, Merrimack Pharmaceuticals, Inc. (MACK), has received the notification from the US Food and Drug Administration (FDA) for the acceptance and the grant of the priority review designation for their New Drug Application (NDA); and (2) its sublicense partner, Baxalta Incorporated, a wholly owned partner of Baxter International Inc. (BAX) has received the acceptance of Market Authorization Application (MAA) from the European Medicines Agency (EMA), of MM-398 (irinotecan liposome injection, also known as “nal-IRI,”) in the treatment of patients with metastatic adenocarcinoma of the pancreas who have been formerly treated with gemcitabine-based therapy.
A priority review designation is granted to medicines that the US FDA determines, have the potential to provide noteworthy improvements in the safety or effectiveness. The aim is for the FDA to take action on the marketing application within 6 months of receipt (contrast with 10 months under standard review) of the NDA submission. .
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development comprise MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has accomplished Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398
Finally, Informatica Corporation (NASDAQ:INFA), gained 0.06%, to $48.49.
Informatica Corporation (INFA), the world’s number one independent provider of data integration software, recently declared that it has been rated as a “Hot Vendor” in Ventana Research’s 2015 Value Index for Product Information Administration (PIM). Informatica rated “Hot” in all evaluation categories, counting ranking first in Manageability, Reliability and Adaptability, for an aggregate score of 95.8/100, making Informatica one of just two companies identified by Ventana as “the current leaders in PIM.”
According to the Ventana Research report, “Informatica is a new entrant in the product information administration market through its acquisition of Heiler Software, which finished second in our previous Value Index, as Informatica did now.”
The Ventana report states that, “In the last two years the company (Informatica) has adapted that attained PIM software and integrated it with its own market-leading data integration technologies. The combination has created a new market force in PIM.
The 2015 Value Index for Product Information Administration uses the Ventana Research methodology to evaluate vendors across five product-related categories: Usability, Manageability, Reliability, Capability and Adaptability. Two additional categories assess Vendor Validation and Total Cost of Ownership/Return on Investment. Solutions vendors rated by Ventana as “Hot” are those that provide the most value to customers.
Informatica Corporation provides enterprise data integration software and services worldwide. Its enterprise data integration products comprise PowerCenter, PowerExchange, and Data Integration Hub, in addition to PowerCenter Express, an entry-level data integration and profiling edition for departments or small to mid-market business, and cloud data integration solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
